Labcorp Holdings annual depreciation and amortization
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Labcorp Holdings Depreciation & Amortization Growth & History (LH)
Labcorp Holdings's depreciation and amortization was $681.1M for fiscal 2025.
View full Labcorp Holdings company overviewLabcorp Holdings annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $681.1M | $37.6M | +5.84% |
| 2024 | 2024-12-31 | $643.5M | $66.2M | +11.47% |
| 2023 | 2023-12-31 | $577.3M | $40.1M | +7.46% |
| 2022 | 2022-12-31 | $537.2M | −$39.8M | −6.90% |
| 2021 | 2021-12-31 | $577.0M | −$47.7M | −7.64% |
| 2020 | 2020-12-31 | $624.7M | $47.5M | +8.23% |
| 2019 | 2019-12-31 | $577.2M | $25.1M | +4.55% |
| 2018 | 2018-12-31 | $552.1M | $18.9M | +3.54% |
| 2017 | 2017-12-31 | $533.2M | $34.0M | +6.81% |
| 2016 | 2016-12-31 | $499.2M | $41.4M | +9.04% |
| 2015 | 2015-12-31 | $457.8M | $212.3M | +86.48% |
| 2014 | 2014-12-31 | $245.5M | $15.4M | +6.69% |
| 2013 | 2013-12-31 | $230.1M | $300,000 | +0.13% |
| 2012 | 2012-12-31 | $229.8M | −$1.6M | −0.69% |
| 2011 | 2011-12-31 | $231.4M | $27.8M | +13.65% |
| 2010 | 2010-12-31 | $203.6M | $8.5M | +4.36% |
| 2009 | 2009-12-31 | $195.1M | $15.4M | +8.57% |
| 2008 | 2008-12-31 | $179.7M | $16.9M | +10.38% |
| 2007 | 2007-12-31 | $162.8M | — | — |
Labcorp Holdings quarterly depreciation and amortization
Q3.08
Q1.09
Q2.09
Q3.09
Q1.10
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q1.12
Q2.12
Q3.12
Q1.13
Q2.13
Q3.13
Q1.14
Q3.14
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $179.0M | $8.7M | +5.11% |
| Q1 2026 | 2026-03-31 | $173.3M | $6.5M | +3.90% |
| Q4 2025 | 2025-12-31 | $173.0M | — | — |
| Q3 2025 | 2025-09-30 | $171.0M | $9.5M | +5.88% |
| Q2 2025 | 2025-06-30 | $170.3M | $13.4M | +8.54% |
| Q1 2025 | 2025-03-31 | $166.8M | $12.3M | +7.96% |
| Q3 2024 | 2024-09-30 | $161.5M | $15.6M | +10.69% |
| Q2 2024 | 2024-06-30 | $156.9M | $14.0M | +9.80% |
| Q1 2024 | 2024-03-31 | $154.5M | $12.4M | +8.73% |
| Q3 2023 | 2023-09-30 | $145.9M | $11.8M | +8.80% |
| Q2 2023 | 2023-06-30 | $142.9M | $31.7M | +28.51% |
| Q1 2023 | 2023-03-31 | $142.1M | −$19.4M | −12.01% |
| Q3 2022 | 2022-09-30 | $134.1M | −$52.0M | −27.94% |
| Q2 2022 | 2022-06-30 | $111.2M | −$75.9M | −40.57% |
| Q1 2022 | 2022-03-31 | $161.5M | −$22.4M | −12.18% |
| Q3 2021 | 2021-09-30 | $186.1M | $33.8M | +22.19% |
| Q2 2021 | 2021-06-30 | $187.1M | $43.2M | +30.02% |
| Q1 2021 | 2021-03-31 | $183.9M | $39.3M | +27.18% |
| Q3 2020 | 2020-09-30 | $152.3M | $8.0M | +5.54% |
| Q2 2020 | 2020-06-30 | $143.9M | $2.3M | +1.62% |
| Q1 2020 | 2020-03-31 | $144.6M | $9.1M | +6.72% |
| Q3 2019 | 2019-09-30 | $144.3M | $11.2M | +8.41% |
| Q2 2019 | 2019-06-30 | $141.6M | $3.1M | +2.24% |
| Q1 2019 | 2019-03-31 | $135.5M | −$7.3M | −5.11% |
| Q3 2018 | 2018-09-30 | $133.1M | $0 | 0.00% |
| Q2 2018 | 2018-06-30 | $138.5M | $11.5M | +9.06% |
| Q1 2018 | 2018-03-31 | $142.8M | $14.7M | +11.48% |
| Q3 2017 | 2017-09-30 | $133.1M | $12.0M | +9.91% |
| Q2 2017 | 2017-06-30 | $127.0M | $1.6M | +1.28% |
| Q1 2017 | 2017-03-31 | $128.1M | $5.7M | +4.66% |
| Q3 2016 | 2016-09-30 | $121.1M | $1.5M | +1.25% |
| Q2 2016 | 2016-06-30 | $125.4M | $8.1M | +6.91% |
| Q1 2016 | 2016-03-31 | $122.4M | $19.8M | +19.30% |
| Q3 2015 | 2015-09-30 | $119.6M | $61.1M | +104.44% |
| Q2 2015 | 2015-06-30 | $117.3M | — | — |
| Q1 2015 | 2015-03-31 | $102.6M | −$142.9M | −58.21% |
| Q3 2014 | 2014-09-30 | $58.5M | $600,000 | +1.04% |
| Q1 2014 | 2014-03-31 | $245.5M | $190.0M | +342.34% |
| Q3 2013 | 2013-09-30 | $57.9M | $300,000 | +0.52% |
| Q2 2013 | 2013-06-30 | $56.9M | $800,000 | +1.43% |
| Q1 2013 | 2013-03-31 | $55.5M | −$1.2M | −2.12% |
| Q3 2012 | 2012-09-30 | $57.6M | −$100,000 | −0.17% |
| Q2 2012 | 2012-06-30 | $56.1M | −$1.7M | −2.94% |
| Q1 2012 | 2012-03-31 | $56.7M | −$1.4M | −2.41% |
| Q3 2011 | 2011-09-30 | $57.7M | $7.1M | +14.03% |
| Q2 2011 | 2011-06-30 | $57.8M | $7.7M | +15.37% |
| Q1 2011 | 2011-03-31 | $58.1M | $8.1M | +16.20% |
| Q3 2010 | 2010-09-30 | $50.6M | $1.1M | +2.22% |
| Q2 2010 | 2010-06-30 | $50.1M | $1.6M | +3.30% |
| Q1 2010 | 2010-03-31 | $50.0M | $2.7M | +5.71% |
| Q3 2009 | 2009-09-30 | $49.5M | $4.3M | +9.51% |
| Q2 2009 | 2009-06-30 | $48.5M | — | — |
| Q1 2009 | 2009-03-31 | $47.3M | — | — |
| Q3 2008 | 2008-09-30 | $45.2M | — | — |
Labcorp Holdings depreciation and amortization trends
Over the last five fiscal years, Labcorp Holdings's depreciation and amortization increased from $624.7M to $681.1M, a change of $56.4M. The latest reported quarter, Q2 2026, shows $179.0M.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Labcorp Holdings source filings ↗Community posts
Labcorp sets new medium-term growth targets and reaffirms its annual outlook
Labcorp ($LH) set medium-term targets for annual revenue growth of 5–8% and adjusted earnings-per-share growth of 8.5–11.5% through 2029. The company also reaffirmed its existing 2026 guidance. The new framework describes the performance ma ...
Labcorp acquires MLM Medical Labs to expand clinical-trial services
Labcorp ($LH) acquired MLM Medical Labs, adding central and specialty laboratory operations in the United States, Germany and South Africa. The company said the purchase expands its biomarker-testing capabilities and improves its ability to ...